Brain-Controlled Exoskeleton Enables Paralyzed Patient to Walk The device cannot be used outside of the lab yet, but the outcomes are bright. Aquadriplegic patient has walked again acknowledgments to a brain-controlled robotic exoskeleton suit being well-tried in the lab, according to a group of investigators in France. Their assemblage were published (October 3) in The Lancet Neurology. Thibault (whose last name was withheld for privacy), 28 years old at the occurrence of the two-year study, was paralyzed from the shoulders down after a cervical spinal cord injury. Researchers constituted two recording devices on the surface of his brain to accumulate and transmit brain signals. The signals were interpreted into motions with a decoding algorithm, which then sent commands to the exoskeleton. Thibault was able to complete various movement tasks such as walking and reaching for targets, according to a press release.Source: Brain-Controlled Exoskeleton Enables Paralyzed Patient to Walk | The Scientist Magazine®
This year’s Nobel Prize in Physiology or Medicine goes to William Kaelin of the Dana-Farber Cancer Institute and Harvard Medical School, Peter Ratcliffe of the University of Oxford and the Francis Crick Institute, and Gregg Semenza of the Johns Hopkins University School of Medicine “for their discoveries of how cells sense and adapt to oxygen availability,” the Nobel Assembly at the Karolinska Institute announced today (October 7). See “Seeking a Cellular Oxygen Sensor” In 1995, Semenza’s lab was the first to identify the genes that encode hypoxia-inducible factor-1 (HIF-1), a transcription factor that alters cellular responses to low oxygen. His group found that HIF-1 responds to low oxygen levels by controlling which genes are used in a cell. The protein enables cancer cells to live in the low-oxygen conditions found within tumors, and helps the body respond to cardiovascular events that limit oxygen flow to parts of the body.
NYU Tandon-drove group crosses boundary expected to convey drugs at the cell level and to build tissue.
Envision an impeccably biocompatible, protein-based medication conveyance framework sturdy enough to get by in the body for over about fourteen days and equipped for giving supported drug discharge. An interdisciplinary research group driven by Jin Kim Montclare, a professorof biomolecular and chemical engineering at the NYU Tandon School of Engineering, has made the principal protein-built hydrogel that meets those criteria, propelling a zone of organic chemistry basic to not exclusively to the eventual fate of medication conveyance, yet tissue building and regenerative prescription.
Hydrogels are three-dimensional polymer organizes that reversibly progress to gel in light of physical or substance improvements, for example, temperature or sharpness. These polymer lcreate attices can epitomize payload, for example, little particles, or give auxiliary framework to tissue building applications. Montclare is lead creator of another paper in the journal Biomacromolecules, which subtleties the making of a hydrogel involved a solitary protein area that shows a significant number of indistinguishable properties from manufactured hydrogels. Protein hydrogels are more biocompatible than engineered ones, and don’t require conceivably dangerous synthetic crosslinkers.